MRNS — Marinus Pharmaceuticals Balance Sheet
0.000.00%
- $30.34m
- $43.35m
- $30.99m
- 29
- 35
- 13
- 14
Annual balance sheet for Marinus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 91.7 | 140 | 123 | 241 | 150 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 1.65 | 3.19 | 6.35 | 3.8 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 94.1 | 146 | 132 | 252 | 165 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.76 | 3.94 | 4.2 | 5.54 | 4.84 |
| Other Long Term Assets | |||||
| Total Assets | 98.8 | 150 | 137 | 260 | 171 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.03 | 10.7 | 40.6 | 25 | 40.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.1 | 13.3 | 83.4 | 144 | 154 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 87.8 | 137 | 53.5 | 116 | 16.8 |
| Total Liabilities & Shareholders' Equity | 98.8 | 150 | 137 | 260 | 171 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |